Ondine Biomedical Inc. OBIMF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -0.90% | -22.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.90% | -22.52% | |||
| Cost of Revenue | -0.88% | -34.95% | |||
| Gross Profit | -0.88% | -13.69% | |||
| SG&A Expenses | -0.89% | 3.66% | |||
| Depreciation & Amortization | -0.98% | 6.74% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.89% | -8.59% | |||
| Operating Income | 0.89% | 7.28% | |||
| Income Before Tax | 0.89% | 3.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.89% | 3.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.89% | 3.16% | |||
| EBIT | 0.89% | 7.28% | |||
| EBITDA | 0.89% | 7.40% | |||
| EPS Basic | 0.90% | 9.76% | |||
| Normalized Basic EPS | 0.00% | 10.39% | |||
| EPS Diluted | 0.90% | 9.76% | |||
| Normalized Diluted EPS | 0.00% | 10.39% | |||
| Average Basic Shares Outstanding | 0.00% | 7.99% | |||
| Average Diluted Shares Outstanding | 0.00% | 7.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||